medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Number 2

<< Back Next >>

Rev Mex Neuroci 2008; 9 (2)

Immunological alterations in the multiple sclerosis

Uribe Jaimes PD, Núñez OL

Language: Spanish
References: 29
Page: 150-153
PDF size: 48.28 Kb.


ABSTRACT

To the multiple sclerosis he is known as a disease desmielinizante of the nervous central system inflammatory and degenerative, who appears basically in the women between 20 and 40 years. In the etiology of this disease there have been involved genetic, immunological and environmental factors.


REFERENCES

  1. Minden SL, Marder WD, Harrold LN, et al. Multiple sclerosis. A statistical portrait. National Multiple Sclerosis Society Report. Cambridge MA. 1991.

  2. CoronaT. Multiple sclerosis in Mexico: hospital cases at the National Institute of Neurology and Neurosurgery, Mexico City. Neurologia 1996; 11(5): 170-3.

  3. Dyment DA. Genetics of multiple sclerosis. Hum Mol Genet 1997; 6: 1693-8.

  4. Siblye WA, Bamford CR, Clark C. Clinical viral infectons and multiple sclerosis. Lancet 1985; 1: 1313-15.

  5. Hemachudha T. MBP as an encephalitogen in encephalomuelitis and polyneuritis following rabies vaccination. N Eng J Med 1987; 316: 369.

  6. Zamvil SS, Steinman I. The T lymphocite in experimental allergic enchepalomyelitis. Ann Rev Immunol 1990; 49: 53-61.

  7. Antel JP, Nicholas MK, Bania MB, et al. Comparison of T8 cell mediated supresor and cytotoxic function in MS. J Neuroimmunol 1986; 12: 215-24.

  8. Gallo P, Piccino M, Pagni S, et al. Immune activation in MS: study of IL-2, sIL-2R and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 1989; 92: 9-15.

  9. Bansil S, Troiano R, Cook SD, et al. Serum soluble IL-2R levels in chronic progressive, stable and steroid treated MS. Acta Neurol Scand 1991; 84: 282-5.

  10. Sharief M, Hentges R. Association between tumor necrosis factor – alpha and disease progression in patients with MS. N Engl J Med 1991; 325: 467-72.

  11. Hartung HP, Michels M, Reiners K, et al. Soluble ICAM-1 serum levels in MS and viral encephalitis. Neurology 1993; 43: 2331-5.

  12. Beck J, Rondot P, Jullien P, et al. TGF like activity produced during regression of exacerbations in MS. Acta Neurol Scand 1991; 84: 452-5.

  13. Chou YK, Bourdette DN, Offner H, et al. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in MS. J Neuroimmunol 1992; 38: 105-14.

  14. Sun JB, Link H, Olsson T, et al. T and B cell responses to myelinoligodendrocyte protein in MS. J Immunol 1991; 146: 1490-5.

  15. Warren KG, Catz I, Johnson E, et al. Anti myelin basic protein and anti proteolipid protein specific forms of MS. Ann Neurol 1994; 35: 280-9.

  16. Martin R, Jaraquemada D, Flerlage M, et al. Fine specificity and HLA restriction of myelin basic protein-specif cytotoxic T cell lines from MS patients and healthy individuals. J Immunol 1990; 145: 540-8.

  17. Jaraquemada R, Martin R, Rosen R, et al. HLA-DR2 is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. J Immunol 1990; 145: 2880-5.

  18. Wucherpfennig KW, Ota K, Endo N, et al. Shared human T cell receptor Vb usage to immunodominant regions of myelin basic protein, Science 1990; 248: 1016-19.

  19. Utz U, Biddison WE, McFarland HF, et al. Skewed T cell repertoire in genetically identical twins with MS. Nature 1993; 364: 243-7.

  20. Pelfrey CM, Trotter JL, Tranquill F, et al. Identification of a novel T cell epitope of human proteolypid protein (residues 40-60) recognized by proliferative and cytolytic CD4 T cells from MS patients. J Neuroimmunol 1993; 46: 33-42.

  21. Chofflon M, Weiner HL, Morimoto C, et al. Decrease of supressor inducer T cells in MS cerebrospinal fluid. Ann Neurol 1989; 25: 494-9.

  22. Svenningson A, Hansson GK, Anderson O, et al. Adhesion molecule expression in crebrospinal fluid T lymphocites: mechanisms in MS, aseptic meningitis and normal controls. Ann Neurol 1993; 34: 155-61.

  23. Sharief MK, Mentges R, Ciardi M, et al. In vivo relationship of IL-2 and soluble IL-2 receptor to blood brain barrier impairment in patients with active MS. J Neurol 1993; 240: 46-50.

  24. Sharief MK, Thompson EJ. In vivo relationship of tumor necrosis factor alpha to blood barin barrier damage in patients with actuve MS. J Neuroimmunol 1992; 38: 27-34.

  25. Traugott U, Reinherz EL, Raine CS. MS: distribution of T cells subsets within active chronic lesions. Science 1983; 219: 308-10.

  26. Sobler RA, Hatler DA, Castro E, et al. The 2H4 (CD45R) antigen is selectively decreased in MS lesions. J Immunol 1988; 140: 2210-14.

  27. Sobel RA, Mitchell ME, Fronderen G, et.al. Intercellular adhesion molecule 1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990; 136: 1309-16.

  28. Freedman MS, Tuijs TG, Selin LK, et.al. Peripheral blood gammadelta T cells lyse fredh human brain derived oligodendrocytes. Ann Neurol 1991; 30: 794-800.

  29. Bö L, Dawson TM, Wesseling S, et al. Induction of nytric oxide synthase in demyelinating region of MS brains. Ann Neurol 1994; 36: 778-86.




2020     |     www.medigraphic.com